{
    "organizations": [],
    "uuid": "21542a9d91e5439fa05f9ecf72b9d4339f70a3ed",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dermira-inc-q1-loss-per-share-142/brief-dermira-inc-q1-loss-per-share-1-42-idUSASC09ZNI",
    "ord_in_thread": 0,
    "title": "Dermira Inc Q1 Loss Per Share $1.42",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Dermira Inc:\n* DERMIRA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* QTRLY LOSS PER SHARE $1.42 * LEBRIKIZUMAB PHASE 2B STUDY ENROLLING PATIENTS, DATA EXPECTED IN FIRST HALF OF 2019\n* IF APPROVED BY U.S. FDA, LAUNCH GLYCOPYRRONIUM TOSYLATE FOR TREATMENT OF AXILLARY HYPERHIDROSIS IN SECOND HALF OF 2018 Source text for Eikon:\nOur ",
    "published": "2018-05-04T04:17:00.000+03:00",
    "crawled": "2018-05-04T16:32:33.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "dermira",
        "inc",
        "dermira",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "qtrly",
        "loss",
        "per",
        "share",
        "lebrikizumab",
        "phase",
        "2b",
        "study",
        "enrolling",
        "patient",
        "data",
        "expected",
        "first",
        "half",
        "approved",
        "fda",
        "launch",
        "glycopyrronium",
        "tosylate",
        "treatment",
        "axillary",
        "hyperhidrosis",
        "second",
        "half",
        "source",
        "text",
        "eikon"
    ]
}